- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04049071
TARGET GCAT Registry
Proposal for Establishment of a UK Post-marketing Surveillance Registry to Study the Effectiveness, Safety and Prescribing Habits of Tocilizumab for the Treatment of Giant Cell Arteritis in the UK National Health Service, Nested Within the Existing Structure of the UK GCA Consortium and UKIVAS Studies
A longitudinal post-marketing surveillance registry nested within the UK GCA Consortium that assesses the effectiveness and safety of tocilizumab in controlling refractory or relapsing forms of GCA in patients who require escalation of therapy to reach sustained remission. Half the patients recruited will have been prescribed tocilizumab (cases) and the other half will be prescribed alternative therapies (controls).
There are four study visits over 18 months: baseline, 6 months, 12 months and 18 months. At each visit data is collected on demographics; diagnosis and investigations; previous and concomitant medications; medical history; co-morbidities, vital signs; smoking and alcohol; disease activity and damage; routine laboratory tests; reason for starting escalation therapy. Safety data is collected on an ongoing basis.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Birmingham, United Kingdom
- Birmingham Heartlands Hospital, Heart of England NHS Foundation Trust
-
Cambridge, United Kingdom
- Addenbrookes Hospital, Cambridge University Hospitals NHS Foundation Trust
-
Derby, United Kingdom
- Royal Derby Hospital, University Hospital of Derby and Burton NHS Foundation Trust
-
Dundee, United Kingdom
- Ninewells Hospital and Medical School, NHS Tayside
-
Edinburgh, United Kingdom
- NHS Lothian, Edinburgh
-
Glasgow, United Kingdom
- Inverclyde Royal Hospital, NHS Greater Glasgow & Clyde
-
Glasgow, United Kingdom
- Royal Alexandra Hospital, NHS Greater Glasgow & Clyde
-
Glasgow, United Kingdom
- Vale of Leven Hospital, NHS Greater Glasgow & Clyde
-
Harrogate, United Kingdom
- Harrogate and District NHS Foundation Trust
-
Keighley, United Kingdom
- Airedale General Hospital, Airedale NHS Foundation Trust
-
Kendal, United Kingdom
- Royal Lancaster & Westmorland General, University Hospitals of Morecambe Bay NHS Foundation Trust
-
Leeds, United Kingdom
- Chapel Allerton Hospital, Leeds Teaching Hospitals NHS Foundation Trust
-
Leicester, United Kingdom
- Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust
-
Liverpool, United Kingdom
- Aintree University Hospital, Aintree University Hospital NHS Foundation Trust
-
Llantrisant, United Kingdom
- Royal Glamorgan Hospital, Cwm Taf University Health Board
-
London, United Kingdom
- Kings College Hospital NHS Foundation Trust
-
London, United Kingdom
- Royal Free Hospital, Royal Free London NHS Foundation Trust
-
London, United Kingdom
- University College London NHS Foundation Trust
-
Luton, United Kingdom
- Luton and Dunstable Hospital, The Luton and Dunstable Hospitals NHS Foundation Trust
-
Manchester, United Kingdom
- Manchester Royal Infirmary, Central Manchester University Hospitals NHS Foundation Trust
-
Newcastle Upon Tyne, United Kingdom
- The Freeman Hospital, The Newcastle-upon-Tyne Hospitals NHS Foundation Trust
-
Northampton, United Kingdom
- Northampton General Hospital
-
Norwich, United Kingdom
- Norfolk and Norwich University Hospital Nhs Foundation Trust
-
Nottingham, United Kingdom
- Queens Medical Centre, Nottingham University Hospitals NHS Trust
-
Oxford, United Kingdom
- Oxford Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Foundation Trust
-
Preston, United Kingdom
- Royal Preston Hospital, Lancashire Teaching Hospitals NHS Foundation Trust
-
Southend-on-Sea, United Kingdom
- Southend University Hospital NHS Foundation Trust
-
Stevenage, United Kingdom
- Lister Hospital, East and North Hertfordshire NHS Trust
-
Torquay, United Kingdom
- Torbay Hospital, Torbay and South Devon NHS Foundation Trust
-
Truro, United Kingdom
- Royal Cornwall Hospitals NHS Foundation Trust
-
Wakefield, United Kingdom
- Dewsbury & District Hospital, Mid Yorkshire Hospitals NHS Trust
-
Wakefield, United Kingdom
- Pinderfields Hospital, Mid Yorkshire Hospitals NHS Trust
-
Wishaw, United Kingdom
- University Hospital Wishaw, NHS Lanarkshire
-
York, United Kingdom
- York Teaching Hospital NHS Foundation Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient must have a diagnosis of GCA and be eligible for the UK GCA Consortium study
- Willing and able to consent
- Have refractory or relapsing GCA as defined by the NHS England commissioning statement for tocilizumab.
- Require treatment escalation
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Other
Cohorts and Interventions
Group / Cohort |
---|
Case
Cases are patients that are prescribed tocilizumab as escalation therapy for relapsing/refractory GCA
|
Control
Controls are those that are prescribed an alternative escalation therapy (not tocilizumab) for relapsing/refractory GCA.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the proportion of eligible patients who achieve sustained partial or complete remission 6 months after the start of tocilizumab
Time Frame: 6 months
|
Data on disease features and lab tests collected at 6 month, compared with that collected at baseline
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the proportion of eligible patients who achieve a sustained complete remission 6 months after the start of tocilizumab
Time Frame: 6 months
|
Data on disease features and lab tests collected at 6 month, compared with that collected at baseline
|
6 months
|
To assess the safety (event reporting) and effectiveness (in terms of prevention of relapse) of tocilizumab compared to other strategies for refractory/relapsing disease in patients with GCA who require escalation therapy.
Time Frame: 18 months
|
Collection of safety data throughout study (non serious adverse events, serious adverse events, adverse events of special interest, special situations, notification of death)
|
18 months
|
To compare characteristics (demographics, disease severity, risk factors for steroid toxicity, contraindications to tocilizumab, concomitant medications) of real-world patients prescribed tocilizumab to clinical trial populations.
Time Frame: 0-18 months
|
All data collected throughout the study period
|
0-18 months
|
To describe relapse rates in patients with GCA treated with tocilizumab at treatment completion (usually 12 months in the UK) and 6 months following discontinuation of tocilizumab
Time Frame: 0-18 months
|
Data on disease features and lab tests collected at month 12 and 18 and compared with that collected at baseline and month 6
|
0-18 months
|
To describe disease activity during the first 6 and 12 months following the start of tocilizumab, compared to other treatment strategies for refractory/relapsing disease
Time Frame: 0-12 months
|
Data collected on disease features, inflammatory markers and vital signs.
|
0-12 months
|
To describe ischaemic complications during the first 6 and 12 months following the start of tocilizumab, compared to other treatment strategies for refractory/relapsing disease
Time Frame: 0-12 months
|
Data collected on disease features and event reporting as appropriate (serious adverse events & non-serious adverse events).
|
0-12 months
|
To describe drug related toxicity during the first 6 and 12 months following the start of tocilizumab, compared to other treatment strategies for refractory/relapsing disease
Time Frame: 0-12 months
|
Data collected on lab results such as HbA1c and medication taken including the dose, reason for changes in dose or discontinuation, documentation of any events relating to drug toxicity.
|
0-12 months
|
To describe patterns of glucocorticoid dosing, including estimated cumulative dose & time to discontinuation of glucocorticoids, in patients with GCA & treated with tocilizumab, compared to other treatment strategies for refractory/relapsing disease
Time Frame: 0-18 months
|
Data on glucocorticoid collected throughout study including dose changes & date of change
|
0-18 months
|
To describe reasons for premature discontinuation of tocilizumab
Time Frame: 0-18 months
|
Reason for premature discontinuation of tocilizumab is captured at the follow up visits.
|
0-18 months
|
To estimate the prevalence of glucocorticoid toxicity (e.g. weight gain, fracture, diabetes, infection, or new psychiatric diagnosis) in patients with GCA who are treated with tocilizumab, compared to other strategies for refractory/relapsing disease
Time Frame: 0-18 months
|
Data collected throughout study on features associated with glucocorticoid toxicity such as those listed within the title
|
0-18 months
|
To invite patients who agree to take part in the current study to consent to being approached to participate in future related studies of their condition, including randomised controlled trials
Time Frame: 0-18 months
|
Keeping a record of those who have been agreed to be contacted for similar studies in the randomised controlled trials
|
0-18 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ann Morgan, University of Leeds
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Skin Diseases
- Immune System Diseases
- Autoimmune Diseases of the Nervous System
- Autoimmune Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Muscular Diseases
- Vasculitis
- Skin Diseases, Vascular
- Vasculitis, Central Nervous System
- Polymyalgia Rheumatica
- Giant Cell Arteritis
- Arteritis
Other Study ID Numbers
- MM05/7307
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Giant Cell Arteritis
-
Matthew J KosterEli Lilly and CompanyCompleted
-
AbbVieActive, not recruitingGiant Cell Arteritis (GCA)United States, Australia, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Netherlands, New Zealand, Norway, Portugal, Romania, Russian Federation, Spain, Sweden, Switzerland, United...
-
University Hospital, GrenobleTerminated
-
Novartis PharmaceuticalsRecruitingGiant Cell Arteritis (GCA)United States, Austria, Belgium, Spain, Greece, Hungary, Turkey, France, Israel, Australia, Switzerland, Germany, Denmark, Argentina, Finland, United Kingdom, Brazil, Chile, Portugal, Poland, Bulgaria, Czechia, Guatemala, Italy, Estonia, ... and more
-
Centre Hospitalier Universitaire DijonRecruitingPatients Relapsing Refractory Giant Cell ArteritisFrance
-
University Hospital, LimogesTerminatedGiant Cell Arteritis in Dependency of ElderlyFrance
-
University Hospital, Basel, SwitzerlandNovartis; Schweizerische Stiftung für die Erforschung der MuskelkrankheitenRecruitingPolymyalgia Rheumatica (PMR) | Giant Cell Arteritis (GCA)Switzerland
-
University Health Network, TorontoCompleted
-
University of OxfordUniversity of LeedsWithdrawnTemporal Arteritis